On the stock market since 2012, it operates in the world of health and science. It has 84,586 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $5.9B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $44.88 per share each year — regular cash for whoever holds the stock.
A loss of $297.9M against $5.9B in annual sales.
At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.
On our five-subject report card, ORPEF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ORPEF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.